Eric Santiago, MD
Internal Medicine · Fpo, APNPI 1457502114
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 696 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 696 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- AbbVie$1K
- Boehringer Ingelheim$809
- Lilly USA, LLC$792
- Pfizer$694
- plus $4K from 26 others
What the payments were for
- Food & beverage$10,59399%
- Education$771%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 107 | $1,717 |
| AstraZeneca | 74 | $1,245 |
| AbbVie(2 entities) | 115 | $1,126 |
| Boehringer Ingelheim | 51 | $809 |
| Lilly USA, LLC | 51 | $792 |
| Pfizer | 44 | $694 |
| GSK | 39 | $613 |
| Amgen | 38 | $594 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $493 |
| Novartis | 22 | $405 |
| Bayer | 19 | $353 |
| Merck | 16 | $261 |
| Abbott | 13 | $245 |
| Sumitomo Pharma America, Inc. | 12 | $195 |
| Biohaven Pharmaceuticals, Inc. | 9 | $145 |
| Johnson & Johnson | 8 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $124 |
| Sanofi-aventis U.S. LLC | 8 | $115 |
| Esperion Therapeutics, Inc. | 5 | $98 |
| Exact Sciences | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Amarin Pharma, Inc. | 2 | $45 |
| Dexcom, Inc. | 2 | $35 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Genentech USA, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| Vertex | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
How this compares
Too few internal medicine providers in APto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $230,267 |
| OzempicSemaglutide | 113 | $186,137 |
| MounjaroTirzepatide | 125 | $179,468 |
| TrulicityDulaglutide | 69 | $114,767 |
| JardianceEmpagliflozin | 66 | $81,793 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $55,734 |
| MyrbetriqMirabegron | 71 | $49,626 |
| GemtesaVibegron | 53 | $42,529 |
| FarxigaDapagliflozin Propanediol | 37 | $36,696 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 41 | $32,278 |
| Repatha SureclickEvolocumab | 34 | $31,073 |
| RybelsusSemaglutide | 18 | $26,142 |
| JanuviaSitagliptin Phosphate | 17 | $24,226 |
| XareltoRivaroxaban | 24 | $20,193 |
| KerendiaFinerenone | 16 | $15,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $792 | $294,235194 claims |
| PfizerEliquis | $694 | $230,267209 claims |
| Novo NordiskOzempic, Rybelsus | $1,717 | $212,279131 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $809 | $114,070107 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $613 | $69,09859 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,245 | $57,22660 claims |
| Astellas Pharma US IncMyrbetriq | $21 | $49,62671 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $195 | $42,52953 claims |
| MerckJanuvia | $261 | $24,22617 claims |
| Johnson & JohnsonXarelto | $129 | $20,19324 claims |
| BayerKerendia | $353 | $15,54016 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $493 | $14,55012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few internal medicine providers in APon file to place this against a meaningful peer group, so we don't.
Other internal medicine in Fpo
- Matthew FowlerFpo$135
- John GilstadFpo$0
- Xin WeiApo$768
- Cynthia ShimApo$489
- Jacob BesslerAndersen Afb Apo$291
- Timothy GockeApo$178
- Richard PaulApo$134
- Joe ZhangApo$131
- Luke RinesApo$48
- Danielle PresleyApo$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.